Rapid 60-Minute Pertussis Molecular Assay Approved

Meridian Bioscience announced that the FDA clearance for its new Bordetella pertussis (B. pertussis) molecular diagnostic test, the fifth assay on the illumigene platform. This test is the first FDA-cleared molecular stand-alone assay for B. pertussis.

Healthcare providers often send away bacterial cultures to reference laboratories which may take more than a week for a result. An earlier diagnosis can reduce the delay in necessary antibiotic treatment for the patient. The illumigene platform utilizes nasopharyngeal swab samples and the procedure takes less than an hour to report a result. The platform amplifies the specific DNA target for B. pertussis detection which allows for a more definitive result.

RELATED: Infectious Disease Resource Center

The illumigene Pertussis assay will be commercially available within 30 days.

For more information call (800) 543-1980 or visit MeridianBioscience.com.